CSF and serum pNfH concentration at early disease stage
| Amyotrophic lateral sclerosis | Controls | ||
| Symptom duration at LP (months) | ≤7.8 | >7.8 | – |
| CSF pNfH (pg/mL) | 2793 (570–17 247)* | 2284 (314–8 100)* | 337 (20–13 669) |
| Serum pNfH (pg/mL) | 276.4 (45.8–1024.2)* | 153.2 (6.0–1000.7)* | 35.7 (6.0–2060.9) |
| ΔALSFRS-R (points/month) | 1.32 (0.14–5.00) | 0.53 (0.04–2.34) | – |
| Slow (n) | 2 | 19 | – |
| Intermediate (n) | 7 | 35 | – |
| Fast (n) | 13 | 9 | – |
Median values and ranges are given.
Kruskal-Wallis with Dunn post hoc correction (*vs ALS: p<0.0001).
ALS, amyotrophic lateral sclerosis; CSF, cerebrospinal fluid; f, female; LP, lumbar puncture; m, male; pNfH, phosphorylated neurofilament heavy chain.